Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

justed EBITDA excludes depreciation and amortization, contingent consideration expense, interest income and expense, income taxes, stock compensation expense and material non-recurring items.  The reconciliation of the non-GAAP measures to the comparable GAAP measure is detailed in the table provided near the end of the press release.

GAAP net loss for the nine months ended September 30, 2011 was $27.1 million ($0.24 per diluted share), compared to GAAP net income of $218.0 million ($1.74 per diluted share) for the nine months ended September 30, 2010.  Non-GAAP adjusted EBITDA was $37.5 million ($0.31 per diluted share) for the nine months ended September 30, 2011, compared to non-GAAP adjusted EBITDA of $51.0 million ($0.43 per diluted share) for the nine months ended September 30, 2010.

As of September 30, 2011, BioMarin had cash, cash equivalents and short and long-term investments totaling $370.0 million, as compared to $412.1 million at the end of June 30, 2011.  The company paid $48.5 million for the purchase of a manufacturing plant in Ireland in the third quarter of 2011.

"Our commercial portfolio has performed well year-to-date, generating enough cash to fund the significant investment in R&D programs," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "For 2011 guidance, we are slightly raising our expectations for the bottom end of Kuvan net product revenue, total net product revenues and total BioMarin revenues.  We are also raising our expectations for 2011 R&D spend due to the acceleration of our clinical programs, including better than expected enrollment in our clinical studies.  We are focused on the successful development of our pipeline and look forward to many key clinical milestones in the coming year."

Net Product Revenue (in millions)Three Months Ended September 30,Nine  Months Ended September 30,20112010$ Change% Change20112010$ Change% C
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Present at the UBS Global Life Sciences Conference
2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
3. BioMarin to Present at the Baird Health Care Conference
4. BioMarin to Present at the Wedbush Life Sciences Conference
5. BioMarin Announces Second Quarter 2011 Financial Results
6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
8. BioMarin to Present at the William Blair Growth Stock Conference
9. BioMarin to Present at the Jefferies Global Healthcare Conference
10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
11. BioMarin Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ), ... and neurologic disorders, announced today the results of a ... Company,s lead compound. Results from the study show that ... inhibit the activation of inflammatory proteins in the blood ... in a Phase 1 clinical trial under a Medicines ...
(Date:7/1/2015)... July 1, 2015 Radiant Insights ... Stationary Oxygen Concentrators Market Shares, Strategy, and Forecasts, ... achieve continuing growth as the aging population worldwide needs ... respiratory conditions where oxygen is able to improve the ... devices have become affordable and support a mobile lifestyle ...
(Date:7/1/2015)... , July 1, 2015 OncoSec Medical Inc. ("OncoSec") ... immunotherapies, today announced that CEO and President Punit Dhillon ... the Company,s listing to The Nasdaq Stock Market at 9:30 ... in New York City .   ... and stakeholders, we are honored to open the Nasdaq to ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3
... 17 Senesco Technologies, Inc. ("Senesco" or the "Company") ... three months ended September 30, 2009. , Net loss for ... $0.01 per share, compared with a net loss of $1,181,406, or ... 2008. This decrease in net loss was primarily the result ...
... DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. (OTC ... begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers who ... are going out today, cover orders received through early ... our company - actually shipping a product to customers ...
Cached Medicine Technology:Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results 2Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results 3Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results 4Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results 5Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results 6Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results 7Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/2/2015)... ... July 02, 2015 , ... It’s no secret that what we consume can have an effect on the body. ... easily feel dehydrated or perhaps even undernourished if not eating enough of the right foods, as ... an easy time of year to overdo it on the food front as well, with sweet ...
(Date:7/2/2015)... ... 2015 , ... Cs &A, the leader in Semi Timing ... and publication of their newest offering to complement the existing line of Market ... Designed in support of coverage for the full spectrum of Semi Timing solutions ...
(Date:7/1/2015)... ... July 01, 2015 , ... In the United States, summer ... many Middle-Eastern countries like Saudi Arabia and Dubai, the summer temperatures are so hot, ... climates. Celebrity dentist Dr. Sam Saleh of ORA Dentistry Spa notes that a trip ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for ... District of West Virginia on June 26th, the Court rejected the Plaintiff’s ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... retail, long term care, specialty, combo, and compounding pharmacy operations, announces the most ... to the Cardinal Health RBC event at the Venetian Las Vegas, ...
Breaking Medicine News(10 mins):Health News:Iryna Lobur Shares Healthy Treats to Eat for Summer 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4
... (MEMPHIS, Tenn. December 10, 2011) Symptoms improved significantly ... a single treatment with gene therapy developed by researchers ... demonstrated to be safe in a clinical trial conducted ... The findings of the six-person study mark the ...
... , FRIDAY, Dec. 9 (HealthDay News) -- ... days after giving birth have an increased risk of ... Researchers examined data from more than 120,000 Danish women ... psychiatric care either as an outpatient or an inpatient ...
... 9 (HealthDay News) -- Many American soldiers who suffer burns ... or rapid decline in kidney function that is potentially deadly. ... acute kidney injury among 692 U.S. military casualties who were ... two different classification systems, the researchers found that rates of ...
... new partnership between the Centre for Reviews and Dissemination ... is launched today., PubMed Health is a new online ... (NCBI) at the US National Library of Medicine (NLM) ... summaries and full text of selected systematic reviews and ...
... BOSTON Cancer of the liver rare in the ... can result from environmental exposures or infections like chronic ... at Dana-Farber Cancer Institute have identified a mechanism in mice ... into cancerous ones. In addition, they demonstrated in a ...
... Premature infants have fewer types of bacteria in their stomachs ... However, the bacteria and other microbes often found in preemies, ... Duke University Medical Center noted. "You see diversity emerge ... to be stuck -- they have fewer types of bacteria ...
Cached Medicine News:Health News:Gene therapy achieves early success against hereditary bleeding disorder 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 3Health News:Psych Episode Near Childbirth May Presage Bipolar Disorder 2Health News:Burn-Casualty Soldiers at High Risk for Kidney Injury, Study Finds 2Health News:Researchers identify a novel therapeutic approach for liver cancer 2Health News:Preemies Infected With More Dangerous Types of Bacteria: Study 2
... Collar and Stabilizer Plastazote® with ... Hook-and-pile closure straps. Chin cradle ... pieces may be interchanged for ... to the standard Philadelphia Collar ...
Urethrotome - non-optical...
Optical Urethrotome for Telescope 2.7 mm for children....
... The USA Elite ... Visual Urethrotomes are utilized ... strictures and bladder neck ... The visual obturator converts ...
Medicine Products: